CN102791879A - 用于诊断乳癌侵袭性和遗传不稳定性的标记 - Google Patents

用于诊断乳癌侵袭性和遗传不稳定性的标记 Download PDF

Info

Publication number
CN102791879A
CN102791879A CN2010800565327A CN201080056532A CN102791879A CN 102791879 A CN102791879 A CN 102791879A CN 2010800565327 A CN2010800565327 A CN 2010800565327A CN 201080056532 A CN201080056532 A CN 201080056532A CN 102791879 A CN102791879 A CN 102791879A
Authority
CN
China
Prior art keywords
polq
breast cancer
gene
patient
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800565327A
Other languages
English (en)
Chinese (zh)
Inventor
C·卡佐
J-S·霍夫曼
J-C·布尔东
A·马沙多达西尔瓦
H·罗什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
INSTITUT CLAUDIUS REGAUD
Universite de Toulouse
Original Assignee
Centre National de la Recherche Scientifique CNRS
INSTITUT CLAUDIUS REGAUD
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, INSTITUT CLAUDIUS REGAUD, Universite Toulouse III Paul Sabatier filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CN102791879A publication Critical patent/CN102791879A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN2010800565327A 2009-11-13 2010-11-12 用于诊断乳癌侵袭性和遗传不稳定性的标记 Pending CN102791879A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09306096.0 2009-11-13
EP09306096A EP2322658A1 (en) 2009-11-13 2009-11-13 Signature for the diagnosis of breast cancer aggressiveness and genetic instability
PCT/EP2010/067401 WO2011058143A1 (en) 2009-11-13 2010-11-12 Signature for the diagnosis of breast cancer aggressiveness and genetic instability

Publications (1)

Publication Number Publication Date
CN102791879A true CN102791879A (zh) 2012-11-21

Family

ID=41647234

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800565327A Pending CN102791879A (zh) 2009-11-13 2010-11-12 用于诊断乳癌侵袭性和遗传不稳定性的标记

Country Status (11)

Country Link
US (1) US8865408B2 (enExample)
EP (2) EP2322658A1 (enExample)
CN (1) CN102791879A (enExample)
AU (1) AU2010317877A1 (enExample)
BR (1) BR112012011247A2 (enExample)
CA (1) CA2780479A1 (enExample)
ES (1) ES2522992T3 (enExample)
IL (1) IL219697A0 (enExample)
IN (1) IN2012DN04944A (enExample)
PT (1) PT2499258E (enExample)
WO (1) WO2011058143A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106011262A (zh) * 2016-06-29 2016-10-12 北京泱深生物信息技术有限公司 子宫内膜癌诊治标志物及其应用
CN112646864A (zh) * 2020-12-30 2021-04-13 杭州联川基因诊断技术有限公司 一种检测esr1基因表达的引物、探针、试剂盒和检测方法
CN112725444A (zh) * 2020-12-30 2021-04-30 杭州联川基因诊断技术有限公司 一种检测pgr基因表达的引物、探针、试剂盒和检测方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156501A1 (en) * 2011-05-18 2012-11-22 Centre National De La Recherche Scientifique (Cnrs) Signature for the diagnosis of cancer aggressiveness and genetic instability
EP2800821B1 (en) * 2012-01-05 2016-11-16 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of lung cancer aggressiveness
CN102994627B (zh) * 2012-06-21 2015-04-15 宁波海尔施基因科技有限公司 一种肿瘤用药个体化指导的检测方法
US9157124B2 (en) 2012-09-18 2015-10-13 Institute For Cancer Research Systems and methods for diagnosing a predisposition to develop colon cancer
FR3019821A1 (fr) * 2014-04-14 2015-10-16 Centre Nat Rech Scient Nouveaux anticorps utiles pour le diagnostic et le pronostic du cancer
US10724100B2 (en) 2015-09-16 2020-07-28 Institute For Cancer Research Systems and methods for treating patients having a genetic predisposition to develop prostate cancer
WO2017062754A1 (en) * 2015-10-07 2017-04-13 New York University Compositions and methods for enhancing crispr activity by polq inhibition
WO2017070198A1 (en) * 2015-10-19 2017-04-27 Dana-Farber Cancer Institute, Inc. Polymerase q as a target in hr-deficient cancers
US12428663B2 (en) 2018-07-11 2025-09-30 The Johns Hopkins University Identification of DNA polymerase theta inactivation mechanism
US11875903B2 (en) 2018-12-31 2024-01-16 Tempus Labs, Inc. Method and process for predicting and analyzing patient cohort response, progression, and survival
US11830587B2 (en) 2018-12-31 2023-11-28 Tempus Labs Method and process for predicting and analyzing patient cohort response, progression, and survival

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077165A1 (en) * 2006-12-22 2008-07-03 Austrian Research Centers Gmbh - Arc Set of tumor markers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633724B1 (en) 2003-03-12 2011-05-04 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1684736B1 (en) 2003-12-01 2011-08-24 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
WO2007001684A2 (en) 2005-05-19 2007-01-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inhibiting dna polymerase beta to enhance efficacy of anticancer agents
JP2010514777A (ja) 2006-12-26 2010-05-06 ファーマサイクリックス，インク． 併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法
SI2209375T1 (sl) 2007-10-03 2014-12-31 Eisai Inc. Spojine inhibitorja PARP in metode uporabe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077165A1 (en) * 2006-12-22 2008-07-03 Austrian Research Centers Gmbh - Arc Set of tumor markers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAWAMURA ET AL.: "DNA polymerase θ is preferentially expressed in lymphoid tissues and upregulated in human cancers", 《INTERNATIONAL JOURNAL OF CANCER》 *
WANG ET AL.: "Mutational Analysis of Thirty-two Double-Strand DNA Break Repair Genes in Breast and Pancreatic Cancers", 《CANCER RESEARCH》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106011262A (zh) * 2016-06-29 2016-10-12 北京泱深生物信息技术有限公司 子宫内膜癌诊治标志物及其应用
CN112646864A (zh) * 2020-12-30 2021-04-13 杭州联川基因诊断技术有限公司 一种检测esr1基因表达的引物、探针、试剂盒和检测方法
CN112725444A (zh) * 2020-12-30 2021-04-30 杭州联川基因诊断技术有限公司 一种检测pgr基因表达的引物、探针、试剂盒和检测方法

Also Published As

Publication number Publication date
EP2499258B1 (en) 2014-08-06
BR112012011247A2 (pt) 2016-11-22
EP2322658A1 (en) 2011-05-18
IL219697A0 (en) 2012-07-31
ES2522992T3 (es) 2014-11-20
EP2499258A1 (en) 2012-09-19
WO2011058143A1 (en) 2011-05-19
US8865408B2 (en) 2014-10-21
IN2012DN04944A (enExample) 2015-09-25
CA2780479A1 (en) 2011-05-19
US20120021935A1 (en) 2012-01-26
PT2499258E (pt) 2014-11-04
AU2010317877A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
CN102791879A (zh) 用于诊断乳癌侵袭性和遗传不稳定性的标记
CN101809169B (zh) 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
AU2011312504B2 (en) Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
JP5690588B2 (ja) 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法
JP2019528081A (ja) 子宮内膜症についてのバイオマーカーとしてのマイクロｒｎａ
US20130089563A1 (en) Method of diagnosing and treating cancer
He et al. CAMTA1, a novel antitumor gene, regulates proliferation and the cell cycle in glioma by inhibiting AKT phosphorylation
CN109468382B (zh) lncRNA在肺腺癌诊疗中的应用
JP2009512439A (ja) 黒色腫におけるｃ−ＫＩＴ発癌遺伝子の変異
CN111979315A (zh) 环状tp63作为肺鳞癌诊断或治疗靶点的应用
CN101189346A (zh) 乳腺癌相关基因znfn3a1
HK1177953A (en) Signature for the diagnosis of breast cancer aggressiveness and genetic instability
CN103827314A (zh) 用于诊断癌侵袭性和遗传不稳定性的标记
Peña-Hernández et al. BAZ2A association with H3K14ac is required for the transition of prostate cancer cells into a cancer stem-like state
Song role and signaling mechanism of IQGAP2 in the progression of bladder cancer
Totoń-Żurańska et al. NRF2-related transcriptomic alterations as a long-term effect of doxorubicin treatment for childhood acute lymphoblastic leukemia
Thomas Characterisation of the long noncoding RNA GHSROS in prostate and breast cancer
Ko et al. miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral
AU2012258223A1 (en) Signature for the diagnosis of cancer aggressiveness and genetic instability

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1177953

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121121